Unknown

Dataset Information

0

A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients.


ABSTRACT: To determine if proinflammatory and prothrombotic biomarkers are differentially upregulated in persistently antiphospholipid antibody (aPL)-positive patients, and to examine the effects of fluvastatin on these biomarkers.Four groups of patients (age 18-65) were recruited: (a) primary antiphospholipid syndrome; (b) systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) (SLE/APS); (c) persistent aPL positivity without SLE or APS (Primary aPL); and (d) persistent aPL positivity with SLE but no APS (SLE/aPL). The frequency-matched control group, used for baseline data comparison, was identified from a databank of healthy persons. Patients received fluvastatin 40 mg daily for 3 months. At 3 months, patients stopped the study medication and they were followed for another 3 months. Blood samples for 12 proinflammatory and prothrombotic biomarkers were collected monthly for 6 months.Based on the comparison of the baseline samples of 41 aPL-positive patients with 30 healthy controls, 9/12 (75%) biomarkers (interleukin (IL)-6, IL1?, vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF)-?, interferon (IFN)-?, inducible protein-10 (IP10), soluble CD40 ligand (sCD40L), soluble tissue factor (sTF) and intracellular cellular adhesion molecule (ICAM)-1) were significantly elevated. Twenty-four patients completed the study; fluvastatin significantly and reversibly reduced the levels of 6/12 (50%) biomarkers (IL1?, VEGF, TNF?, IP10, sCD40L and sTF).Our prospective mechanistic study demonstrates that proinflammatory and prothrombotic biomarkers, which are differentially upregulated in persistently aPL-positive patients, can be reversibly reduced by fluvastatin. Thus, statin-induced modulation of the aPL effects on target cells can be a valuable future approach in the management of aPL-positive patients.

SUBMITTER: Erkan D 

PROVIDER: S-EPMC3986270 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients.

Erkan Doruk D   Willis Rohan R   Murthy Vijaya L VL   Basra Gurjot G   Vega JoAnn J   Ruiz-Limón Patricia P   Carrera Ana Laura AL   Papalardo Elizabeth E   Martínez-Martínez Laura Aline LA   González Emilio B EB   Pierangeli Silvia S SS  

Annals of the rheumatic diseases 20130809 6


<h4>Objective</h4>To determine if proinflammatory and prothrombotic biomarkers are differentially upregulated in persistently antiphospholipid antibody (aPL)-positive patients, and to examine the effects of fluvastatin on these biomarkers.<h4>Methods</h4>Four groups of patients (age 18-65) were recruited: (a) primary antiphospholipid syndrome; (b) systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) (SLE/APS); (c) persistent aPL positivity without SLE or APS (Primary aPL); and  ...[more]

Similar Datasets

| S-EPMC9384505 | biostudies-literature
2017-08-23 | GSE80342 | GEO
| S-EPMC5933765 | biostudies-literature
2015-08-27 | E-GEOD-65405 | biostudies-arrayexpress
2015-08-27 | GSE65405 | GEO
| S-EPMC7383282 | biostudies-literature
| S-EPMC4348870 | biostudies-literature
| S-EPMC8266739 | biostudies-literature
| S-EPMC8569350 | biostudies-literature
2023-05-24 | GSE143506 | GEO